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Validation of treatment plan quality and dose calculation accuracy is essential for new
radiotherapy techniques, including volumetric modulated arc therapy (VMAT). VMAT delivers
intensity modulated radiotherapy treatments while simultaneously rotating the gantry, adding an
additional level of complexity to both the dose calculation and delivery of VMAT treatments
compared to static gantry IMRT. The purpose of this project was to compare two VMAT systems,
Elekta VMAT and Varian RapidArc, to the current standard of care, IMRT, in terms of both treatment
plan quality and dosimetric delivery accuracy using the Radiological Physics Center (RPC) head and
neck (H&N) phantom. Clinically relevant treatment plans were created for the phantom using typical
prescription and dose constraints for Elekta VMAT (planned with Pinnacle3 Smart Arc) and RapidArc
and IMRT (both planned with Eclipse). The treatment plans were evaluated to determine if they were
clinically comparable using several dosimetric criteria, including ability to meet dose objectives, hot
spots, conformity index, and homogeneity index. The planned treatments were delivered to the
phantom and absolute doses and relative dose distributions were measured with thermoluminescent
dosimeters (TLDs) and radiochromic film, respectively. The measured and calculated doses of each
treatment were compared to determine if they were clinically acceptable based upon RPC criteria of
±7% dose difference and 4 mm distance-to-agreement. Gamma analysis was used to assess dosimetric
accuracy, as well. All treatment plans were able to meet the dosimetric objectives set by the RPC and
had similar hot spots in the normal tissue. The Elekta VMAT plan was more homogenous but less
conformal than the RapidArc and IMRT plans. When comparing the measured and calculated doses,
all plans met the RPC ±7%/4 mm criteria. The percent of points passing the gamma analysis for each
iv

treatment delivery was acceptable. Treatment plan quality of the Elekta VMAT, RapidArc and IMRT
treatments were comparable for consistent dose prescriptions and constraints. Additionally, the
dosimetric accuracy of the Elekta VMAT and RapidArc treatments was verified to be within
acceptable tolerances.
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Chapter 1
1.1

Introduction

Statement of Problem
Volume modulated arc therapy (VMAT) is a radiotherapy technique that delivers intensity

modulated radiation therapy (IMRT) while simultaneously rotating the gantry. VMAT utilizes
continuous gantry rotation, dynamic beam modulation, and variable dose rate to deliver conformal
treatments.
VMAT evolved from a technique called intensity modulated arc therapy (IMAT), first
proposed by Cedric Yu as an alternative to tomotherapy (1). IMAT was implemented on an existing
linear accelerator (linac) and delivered treatments volumetrically, rather than slice by slice. Yu’s
technique used a multi-leaf collimator (MLC) to shape the beam dynamically while the gantry
rotated and used multiple overlapping arcs. Each arc delivered one subfield of an intensity modulated
treatment at each angle. IMAT was similar to the idea of step-and-shoot IMRT, which delivers twodimensional intensity distributions from each static gantry position using several subfields. However,
in IMAT, each subfield at a specific gantry angle would be delivered by separate arcs. The number
of overlapping arcs depended on the complexity of the intensity distribution desired. Two to five arcs
were typically required for clinical delivery of IMAT (2). Although Yu first proposed inverse
planning for IMAT (1), forward planning was used for its actual implementation (2). During
planning, arcs were approximated as multiple fixed fields at gantry angles separated by 5-10°. The
plans mostly used three to five arcs and the final dose calculation approximated each arc as fixed
fields at 10° gantry spacing.
Yu recognized that the forward planning techniques he implemented did not fully utilize the
capabilities of IMAT to deliver conformal treatments. However, there were several challenges to
developing effective planning and dose calculation techniques. Physical limitations of the linac,
1

including leaf travel speed, dose rate, and gantry rotation speed, complicated planning and affected
the efficiency of treatments (1-3). Also, determining the optimal gantry spacing to approximate the
arcs was a trade-off between optimization time, calculation time and accuracy (3).
In 2008, Karl Otto proposed the VMAT technique as a solution to the gantry angle sampling
resolution problem for optimizations and dose calculations (3). A fine sampling improved the dose
accuracy, but the limited MLC motion between small gantry angles restricted the optimization
flexibility and increased the time of optimization. A coarser sampling allowed for greater MLC
motion between gantry angles and, therefore, more freedom in the optimization, but provided a less
accurate representation of the actual treatment. Otto’s solution was to use an aperture-based
optimization scheme in which sampling of gantry angle and MLC position was progressively
increased. It began with a coarse sampling of static gantry positions and MLC aperture shapes and
ended with a high resolution sampling to accurately model the dose delivered. MLC motion was
more restricted as the number of samples increases, reducing the flexibility of the optimization, but
increasing the accuracy of the dose calculation (3).
The concept of VMAT introduced by Otto led to the development of commercial VMAT
treatment planning and delivery techniques, including Elekta VMAT (Elekta AB, Stockholm,
Sweden), planning with Pinnacle3 SmartArc (Philips Medical, Madison, WI), and Varian
RapidArc™ with Eclipse treatment planning (Varian Medical Systems, Palo Alto, CA). To deliver
conformal treatments, these VMAT techniques utilize continuously variable gantry position and
speed, dose rate, and MLC aperture.
The VMAT techniques are marketed as delivering treatment plans equivalent to IMRT in a
single arc while potentially requiring shorter treatment times and less monitor units (MU) than static
gantry IMRT. For new techniques it is important for such claims be verified in practice prior to the
technique’s widespread use. The dose distributions achievable by VMAT techniques should be
2

compared to the standard of care for multiple treatment sites and geometries. Thorough comparisons
of dose distributions achieved by treatments can help clinicians make decisions about patient
radiotherapy treatments. If VMAT has plan quality that is equivalent to IMRT but with less MU and
shorter treatment times, clinicians may choose VMAT to reduce the time a patient spends on the
table and reduce the leakage radiation a patient receives as a result of fewer MU.
The claims about treatment delivery time and MU have been examined by several
researchers. They have found that the treatment times for VMAT using one or two arcs are
significantly reduced when compared to both 3D conformal and IMRT treatments (4-7). One study
found that for head and neck cancers, one and two arc RapidArc treatments had an average reduction
in MU of 59% from seven field sliding window IMRT (6). In this study, two arc treatments required
5% more MU than single arc treatments.
Plan quality of VMAT treatments has been compared with IMRT in several studies. In a
planning study of twelve head and neck cancers, RapidArc one and two arc treatments were
compared to seven field sliding window IMRT and was found to have similar sparing of organ at risk
(OAR) (6). The homogeneity was best for two arc RapidArc and worst for single arc plans. These
complex plans had two planning treatment volumes (PTV) treated to different prescriptions, a boost
PTV and an elective PTV. In the boost PTV, the two arc RapidArc plan was significantly less
conformal than IMRT. The authors concluded that two arc RapidArc treatment plans were similar to
the IMRT dose distributions. It is important to note that in this study the versions of RapidArc
planning used, preclinical Eclipse 8.2.16 and clinical Eclipse 8.2.22, did not allow simultaneous
optimization of more than one arc, which is supported in current versions (6).
A different study compared RapidArc plans to IMRT for four virtual, water equivalent
phantoms with variations of PTV and OARs (4). They found that RapidArc had better conformity
and homogeneity and was better able to meet the plan objectives than five and nine field sliding
3

window IMRT. They also concluded that RapidArc plans with two arcs achieved better dose
distributions than single arc plans (4).
Another planning study compared IMRT and Elekta VMAT planned with Pinnacle3
SmartArc for six prostate and six head and neck patients (7). In this study, they concluded that the
Elekta VMAT plans were comparable to IMRT in target coverage and critical structure sparing. The
authors also noted that Elekta VMAT showed promise in complex head and neck cases (7).
Plan comparison studies are necessary to help clinicians determine which treatment
techniques are best for specific treatment sites and geometries. However, the quality of treatment
plans is subject to the abilities of the planner and the time spent on each plan. Thorough assessment
of the treatment plans generated by a technique must be conducted by several planners in order to
make clinicians fully aware of the quality of plans that VMAT techniques can achieve. We need
more evidence that VMAT plans can be of comparable quality to IMRT, especially for more
difficult, complex geometries, such as head and neck cancers, where there can be multiple, large
treatment volumes with nearby critical structures. Additionally, no study has yet compared the
various VMAT techniques directly to determine if the plan quality varies between the techniques.
In addition to studying the quality of dose distributions achieved by VMAT techniques in
comparison with IMRT, the delivery accuracy of the dose calculated by treatment planning systems
(TPS) has been investigated in several studies. For a new technique, verifying the accurate delivery
of dose distributions is an important part of the quality assurance (QA) process prior to the
technique’s implementation. In one study, the accuracy of RapidArc dose calculation was evaluated
by a Monte Carlo study of oropharynx radiotherapy (8). In this study, they compared Monte Carlo
and the treatment planning calculation and determined that the accuracy of RapidArc dose
calculation was adequate for clinical use when using a 2.5 mm dose grid.
Another study evaluated the accuracy of RapidArc dose delivery by patient specific
verification for nine treatment plans for prostate and head and neck cancers (9). The plans were
4

delivered to a Scandidos Delta4® (Scandidos, Uppsala, Sweden), a cylindrical phantom with arrays
of diodes, which was calibrated to an ionization chamber. The measured and calculated doses were
compared using gamma analysis with 3% dose difference and 3 mm distance-to-agreement (DTA)
criteria. They found that greater than 95% of the points passed in all cases and concluded that dose
distributions delivered by RapidArc corresponded well with the planned treatments (9).
The accuracy of Elekta VMAT dose calculation for prostate and lung cancer plans was
evaluated by measurements in a different study (5). One lung plan was delivered to a Delta4
phantom. Two prostate plans were delivered to a stack of Solid Water® (Gammex, Inc., Middleton,
WI) and the dose was measured by an ionization chamber. One of the prostate plans was also
delivered to the Delta4 phantom. For all tests, gamma analysis was used to evaluate dose delivery
accuracy with 3% dose difference and 3 mm DTA criteria. For all treatments delivered to the Delta4
phantom, greater than 95% of the points passed. The dose measured by the ionization chamber in the
Solid Water stack was less than 3% different from the calculated dose for both prostate treatments.
The authors concluded that the measured and calculated dose distributions agreed well (5).
In another study the dose distributions of RapidArc plans for head and neck radiotherapy
were measured in a QA phantom with GAFCHROMIC® EBT (International Specialty Products,
Wayne, NJ) films in several coronal planes (6). The dose verification was evaluated using gamma
analysis with 3% dose difference and 2 mm DTA criteria. For plans with one and two arcs, the
average passing rate was greater than 97% and greater than 99%, respectively. In this study, one case
compared single and two arc plans to IMRT and found that the two arc plan was the best with 99.1%
of points passing. In comparison, IMRT had 96.4% passing. The authors noted that although EBT
film provides good spatial resolution (0.3 mm), it is a less accurate and stable method of dosimetry
than ionization chamber arrays. In conclusion, they determined that RapidArc treatments were
accurately delivered (6).
5

The accurate delivery of calculated dose distributions was evaluated in another study for six
prostate and six head and neck treatment plans created using Pinnacle3 SmartArc for Elekta VMAT
(7). The MatriXX™ 2D ionization chamber array in a MultiCube™ phantom (IBA Dosimetry Inc.,
Memphis, TN) was used for the plan QA. The gamma analysis was used to evaluate accuracy using a
3% dose difference and 3 mm DTA criteria. For the prostate and head and neck plans, the average
passing rate was 98.9% and 98.3%, respectively. In comparison, the IMRT passing rates were 98.5%
and 97.7%. The authors concluded that Elekta VMAT accurately delivered the planned treatments
(7).
All of the dose delivery verifications have been similar to the type of dose verification
employed for patient specific QA. Until now, no study has been conducted that uses a standardized
and recognized method to verify that calculated doses are accurately delivered. Dose verification is
necessary to assure physicists and clinicians of the accuracy with which patient treatments are
delivered. This is especially important for complex treatments, such as in head and neck cancers,
where conformal treatments need substantial intensity modulation to generate steep dose gradients.
In this project, we evaluated the plan quality of two VMAT techniques, Elekta VMAT
planned with Pinnacle3 SmartArc and Varian RapidArc, for a complex head and neck phantom
radiotherapy treatment and compared the treatment plans to the current standard of care, IMRT.
Additionally, the delivery accuracy of the calculated doses was evaluated using the protocol
established by the Radiological Physics Center (RPC) for head and neck IMRT. This standardized
protocol is used by the Radiation Therapy Oncology Group to credential institutions participating in
clinical trials.

6

1.2

The Radiological Physics Center and Anthropomorphic QA Phantoms
The Radiological Physics Center (RPC) was founded in 1968 as a National Cancer Institute

(NCI) funded group with the mission to ensure that “institutions participating in clinical trials deliver
prescribed radiation doses that are clinically comparable and consistent” (10). In multi-clinic studies,
it is essential that radiation therapies delivered across all participating clinics are similar and that
results are not skewed because of dosimetric differences between clinics. The RPC monitors the
participating institutions by performing quality reviews through its on-site dosimetry review visits
and off-site remote auditing techniques. The off-site auditing program includes:
•

A mailable TLD program to verify machine output

•

Comparison of the institutions’ dosimetry data with RPC standard dosimetry data

•

Evaluation of reference or actual patient calculations to verify treatment planning
algorithms

•

Review of the institutions’ written QA procedures and records

•

Mailed anthropomorphic phantoms to verify tumor dose delivery for special
advanced treatment techniques such as IMRT, stereotactic radiosurgery, etc.

•

Credentialing of institutions for participation in specific protocols

•

Retrospective review of treatment records for patients entered into cooperative
clinical trials.

The purpose of the anthropomorphic phantom audit process is to assess an institution’s
ability to image the phantom, develop a specific treatment plan, and deliver the dose according to
specific protocol guidelines or instructions. The phantom is treated as if it were an actual patient. The
RPC currently has five anthropomorphic phantoms, a stereotactic radiosurgery head phantom, an
IMRT head-and-neck phantom, a thorax phantom, a liver phantom, and a pelvic phantom. The basic
design of each phantom is similar and consists of an outer plastic shell in the appropriate anatomical
7

shape. The shell is filled with water to represent soft tissue and has a compartment that houses the
imageable targets and organs at risk where dosimeters are located. Radiochromic film and TLD are
used for relative and absolute dose measurements, respectively. The films are located in two major
planes and the TLD is used to normalize the film readings as well as measure the dose at a point.
Once the phantom has been irradiated, it is returned to the RPC where the dosimeters are analyzed
and compared to the institution’s treatment planning system’s dose calculations.
These phantoms are mailed to institutions that participate in cooperative clinical trials as a
means to remotely evaluate their ability to plan and deliver dose within specific protocol criteria for
field localization and dose delivery to targets and critical structures. Some radiation therapy clinics
may be replacing IMRT with VMAT for certain treatment sites. In order to allow VMAT users in
RTOG clinical trials involving IMRT, the RPC must ensure that VMAT treatments can deliver
clinically comparable treatments to IMRT.

8

1.3

Hypothesis and Specific Aims
We hypothesized that VMAT techniques generate treatment plans of comparable quality to

IMRT and accurately deliver the calculated dose for complex head and neck treatments.

The hypothesis was tested by the following specific aims:
1) We created clinically relevant treatment plans for the RPC IMRT head and neck phantom
from typical prescription and dose constraints for 1) Elekta VMAT planned with Pinnacle3
SmartArc, 2) Varian RapidArc and 3) 6 MV IMRT.
2) We evaluated the plan quality of the two VMAT and one IMRT head and neck treatment
plans to determine if they were clinically comparable.
3) We delivered the three planned treatments to the head and neck phantom and measured the
dose distribution from each.
4) We compared the measured and calculated doses using clinically acceptable criteria of ±5%
dose difference and 3 mm DTA.

9

Chapter 2
2.1

Methods and Materials

VMAT Techniques Evaluated in This Study

2.1.1

Elekta VMAT Planned with Pinnacle SmartArc

The first VMAT technique evaluated in this study was a treatment plan generated using the
SmartArc module in Pinnacle version 9 (Philips Medical, Madison, WI) and delivered using an
Elekta Synergy linac (Elekta AB, Stockholm, Sweden). Pinnacle’s VMAT treatment planning is
based on work by Bzdusek, et al (11). It uses an inverse-planning approach based on dose-volume
objectives that generates treatment plans with dynamic MLC and variable dose rate and gantry
rotation speeds. The optimization takes into account the machine constraints in order to develop a
deliverable plan.
First, the user sets up the arcs for optimization and inputs parameters such as arc length,
collimator and couch angle, maximum arc delivery time, and final gantry spacing. Additionally, the
TPS can generate additional arcs to be optimized simultaneously using the same parameters as the
initial arc, but with opposite rotation direction. This is known as the dual arc feature. The initial
optimization step generates fluence maps at a coarse resolution of 24° around each arc. Once this
optimization has converged, each fluence map is converted to two to four MLC segments, depending
on the extent of intensity modulation. Of these segments, the two with the most open leaf pairs are
kept per initial angle. These segments are redistributed evenly around the arc. The MLC segments
are now located every 8°. If the dual arc feature is employed, five MLC segments are generated per
initial angle and two are kept per arc. In this case, the MLC segments are distributed in a manner that
reduces leaf travel in each arc.
The next optimization step uses Pinnacle’s Direct Machine Parameter Optimization (DMPO)
on the existing control points. The MU and leaf positions for each control point and arc delivery time
10

are all variables included in the optimization. These variables are limited by the machine and user
specified constraints, such as maximum and minimum dose rate and gantry rotation speed, maximum
leaf speed, and maximum arc delivery time.
To improve the accuracy of the dose calculation during DMPO, the arc sampling resolution
is reduced to the final gantry spacing by linearly interpolating leaf segments between the existing
control points. The typical final gantry spacing is 4°, resulting in 91 control points. The interpolated
control points are only used to improve the dose calculation accuracy and are not included in the
DMPO. During optimization the dose is calculated using the Singular Value Decomposition (SVD)
dose engine, a fast pencil beam algorithm that accounts for tissue heterogeneities in the primary
beam. Once the machine parameters have been optimized, the jaw positions are determined.
The final dose is calculated using a convolution/superposition algorithm, either Adaptive
Convolve or Collapsed-Cone Convolution, and each arc is approximated as 91 control points,
assuming the typical final gantry spacing of 4° was selected by the user. In this study, we used the
Adaptive Convolve dose calculation algorithm in Pinnacle. In flat areas, the dose grid is sampled at
every fourth point and the dose in between is interpolated. The algorithm will switch to a full
sampling if the dose grid cannot be interpolated accurately. The convolution/superposition
algorithms in Pinnacle model the primary energy fluence and the head scatter and adjust for
heterogeneities.
The control point information of the treatment plan, including MU and MLC aperture, is
then transferred to the treatment machine. The control system of the linac, an Elekta Synergy in our
study, determines the dose rate and gantry speed based on the plan information.
2.1.2

Varian RapidArc

The second VMAT technique evaluated in this study was RapidArc, which was planned in
Eclipse version 8.6 and delivered on a Varian Clinac iX linac (Varian Medical Systems, Palo Alto,
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CA). Varian developed RapidArc based on the work of Otto and his novel optimization scheme,
which Varian has termed their Progressive Resolution Optimizer (PRO) algorithm (3). Like
Pinnacle’s algorithm, it uses dose-volume objectives for an inverse-planning approach. The final
plans have dynamic MLC, variable dose rate and variable gantry rotation speeds. The final dose is
calculated using the Anisotropic Analytical Algorithm (AAA).
After the user has setup up the basic arc parameters, including arc length and collimator
angle, the PRO begins optimizing each arc by modeling it as a small number of equally-spaced static
control points with the same initial dose rate and MLC aperture conforming to the target shape.
Then, the MLC aperture and dose rates are varied iteratively and the dose is calculated at each
iteration point. The dose is calculated by first determining the fluence from the MLC aperture and
dose rate and then converting it to dose using Eclipse’s Multi-Resolution Dose Calculation (MRDC)
algorithm, a fast convolution superposition algorithm that corrects for heterogeneities for the primary
dose component. A cost function based on the dose-volume objectives set is used to determine if
each variation should be kept. The algorithm then steps through various stages of resolution in which
it adds control points to each arc progressively and continues to optimize all MLC shapes and dose
rates. The final resolution level finishes with 177 control points per arc, which leads to control points
approximately every 2° for a 360° arc.
Once the optimization has finished, Eclipse uses the AAA to calculate dose, with each arc
approximated as 177 static control points. AAA models the treatment beam as beamlets of multiple
sources: the primary photons generated in head and secondary sources scattered from the linac head,
including the extra-focal photons and the contaminating electrons. The AAA dose engine also
accounts for tissue heterogeneities.
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2.2

The RPC Anthropomorphic IMRT Head and Neck Phantom
The phantom used throughout this study was an anthropomorphic head and neck phantom

designed and constructed by the RPC for credentialing of institutions participating in RTOG head
and neck protocols involving IMRT. The phantom, shown in Figure 2-1, was designed to mimic the
geometry of this treatment site and to hold radiation dosimeters for measuring the dose delivered to
the phantom. The phantom was constructed of materials that are tissue-equivalent.
The phantom consists of a plastic outer shell shaped like a human head and neck. The watertight shell is hollow except for a polystyrene insert and can be filled with water to simulate the
human tissue surrounding the insert (12). There are
plugs in the bottom of the phantom through which water
can be filled and drained from the phantom.
The removable dosimetry insert, seen next to the
phantom in Figure 2-1, contains the treatment volumes
and places to insert radiation dosimeters. It is 13 cm in
height, 10.5 cm wide, and 7.5 cm long (12). The
dosimetry insert has two halves that can be separated for
the insertion and removal of dosimeters. Figure 2-2

Figure 2-1 RPC IMRT head and neck
phantom with dosimetry insert removed

shows the superior half of the insert next to an axial CT image of a cross-section of the insert. The
structures simulated in the insert are indicated in Figure 2-2 and include two solid water PTVs and an
acrylic OAR representing the spinal cord. The primary PTV represents an orophanryngeal tumor and
the secondary PTV represents the peripheral nodes. The densities of the materials in the insert are
sufficiently different so they are readily visualized on CT images without having a significant effect
on the treatment fields. The difference in atomic number of the materials is also insignificant for
treatment. The secondary PTV and OAR are cylinders with their axes in the superior-inferior
13

Figure 2-2 Picture (left) and axial CT image (right) of phantom insert with the anterior edge on top

direction and the dimensions shown in Table 2-1 (12). The primary PTV is in the shape of a cylinder
oriented in the same direction as the other structures, but with a portion cut out on its posterior side
where it wraps around the abutting OAR volume.
Table 2-1 Dimensions of structures in the phantom insert

Structure

Diameter (cm)

Length (cm)

Primary PTV
Secondary PTV
Organ at risk

4
2
1

5
5
13

As shown in Figure 2-2, the inner side of each insert half has four holes drilled for holding
thermoluminescent dosimeter (TLD) capsules to measure absolute dose in eight locations. The TLD
capsules are placed in pairs, with one TLD in the superior half of the insert and another in the same
location in the inferior half. There are two pairs of TLD in the primary PTV offset from the center (a
posterior and an anterior pair) and a pair in the center of both the secondary PTV and the OAR.
There are three radiochromic films placed in the insert to measure the dose distribution in the
axial and sagittal planes. There is one film in the axial plane where the two halves of the insert meet
and two films in the sagittal plane bisecting the primary PTV, one in each half of the insert. The gap
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for the sagittal film in the superior half of the insert is shown in Figure 2-2. The sagittal films have a
cutout where the TLDs in the OAR are located.
On the axial face of the inferior insert, pins are located in three of the corners to poke holes
in the film. Additionally, there are five tiny holes drilled in the outer left side of the insert through
which a small tool can be inserted to pierce the sagittal films. The holes left by piercing the film are
useful for registering the film to the treatment plan later. More details are provided in section 2.5.4
Film, Plan, and Phantom Registration for more details about film and treatment plan registration.

2.3

Treatment Planning
To determine if the two VMAT techniques evaluated in this study were clinically

comparable to IMRT for head and neck radiotherapy, we created clinically relevant treatment plans
for the RPC IMRT head and neck phantom from common prescription and dose constraints for each
technique evaluated in this study: Elekta VMAT planned with Pinnacle3 SmartArc, Varian RapidArc
and 6 MV IMRT.
2.3.1

Phantom Imaging

We performed a CT simulation of the phantom to acquire images of the phantom for
treatment planning. We positioned the phantom supine and “head-first” on the table and used the
lasers to place external radiopaque markers on the phantom. Next, we placed masking tape where the
lasers crossed on the left and right sides and face of the phantom and drew crosshairs to mark the
treatment isocenter. We then took a scout image of the phantom and set the scan extent to include
enough margin superior and inferior of the phantom insert to include the effects of scatter in the dose
calculation.
For the Elekta VMAT treatments, we simulated the phantom using a GE LightSpeed® RT
16-slice CT scanner (GE Healthcare, Waukesha, WI). The CT simulation used the parameters
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specified by the protocol for a stereotactic head and neck patient at Mary Bird Perkins Cancer
Center. The protocol generated 1.25 mm thick images. CT data were imported into the Pinnacle3
TPS for the Elekta VMAT treatment planning.
For the IMRT and RapidArc treatments, we simulated the phantom using a Philips Brilliance
64-slice CT scanner (Philips Healthcare, Andover, MA) and the AcQSim workstation. The CT
simulation used the parameters specified by the MD Anderson protocol for a head and neck patient,
but with the slice thickness reduced from 2.5 mm to 1.5 mm to better visualize the TLDs in the
phantom. The CT data for the IMRT and RapidArc treatments were imported into the Eclipse TPS
for planning.

2.3.2

Dose Prescription and Constraints

The same treatment planning objectives were used for all treatment plans and were based on
RPC specifications. These criteria were derived from a head and neck prescription for the RTOG
protocol 0022: 66 Gy to the primary PTV (the tumor) and 54 Gy to the secondary PTV (the
peripheral node). However, these high doses are out of the useful range for GafChromic® EBT2 film
and have been scaled down by a factor of ten for the RPC phantom test case resulting in a primary
prescribed dose of 6.6 Gy and secondary dose
of 5.4 Gy. At least 95% of the primary PTV

Table 2-2 Dosimetric criteria set by the RPC and
used for planning all treatments

volume must receive its prescription dose (D95%

Structure

≥ 6.6 Gy). Also, 95% of the secondary PTV

Primary PTV

must receive at least 5.4 Gy (D95% ≥ 5.4 Gy).
The OAR simulates the spinal cord, so it was
not allowed to receive more than 4.5 Gy, one-

Secondary PTV

Dosimetric Criteria
D95% ≥ 6.60 Gy
D99% ≥ 6.14 Gy
D95% ≥ 5.40 Gy
D99% ≥ 5.03 Gy

Normal tissue

max dose ≤ 7.26 Gy

Organ at risk

max dose < 4.50 Gy

tenth of the 45 Gy dose limit for the spine.
Additional treatment planning criteria included minimizing the hot spots and that 99% of each target
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volumes must receive more than 93% of that target’s
prescription dose. These criteria are summarized in
Table 2-2.

2.3.3

Volume Delineation

Using the image segmentation tools in each
corresponding TPS, we contoured the two PTVs and the
OAR without any expansions (see Figure 2-3). A total
body structure was generated, automatically in Eclipse
and manually in Pinnacle. We created a normal tissue

Figure 2-3 Contoured structures in
Eclipse: primary PTV (blue), secondary
PTV (yellow), and OAR (red)

structure by subtracting the two PTV volumes from the total body structure. We also contoured each
of the eight TLD. In the Eclipse TPS, the TLD had to be converted to high resolution segments
before adequate contouring was possible.

2.3.4

Treatment Plans

In the TPS, we localized the plans to the radiopaque external fiducials indicating the
simulation isocenter, which can be seen on the CT image shown in Figure 2-3. We placed the
treatment isocenter at the geometric center of the two PTV structures. To do this, we made a single
structure from both the primary and secondary PTVs. We determined the couch shifts necessary to
move from the simulation isocenter to the
treatment isocenter.
The treatment couch for each of the
three treatment plans was defined as follows.
For the SmartArc plan, we removed the
simulation couch. For the RapidArc and IMRT
Figure 2-4 Couch structure (purple) inserted for
the IMRT and RapidArc plans

17

plans, we added the Exact® couch top with flat panel structure with the rails in the out position. This
couch is shown in Figure 2-4 and represents the actual linac couch on which the corresponding
treatments were delivered.
The treatments were planned based on the typical clinical head and neck radiotherapy
parameters of the institution in which the treatments were delivered. Both VMAT plans consisted of
two full coplanar 6 MV arcs. The Elekta VMAT plan (planned with Pinnacle SmartArc) used a 45°
collimator for both arcs and the RapidArc plan had a collimator offset of ±15° (345° and 15°). The
IMRT plan used nine coplanar, equally-spaced 6 MV beams (200°, 240°, 280°, 320°, 0°, 40°, 80°,
and 160° seen in Figure 2-5) and a 0° collimator was set. The couch was set at 0° for all plans.
We set the final gantry spacing of the Pinnacle SmartArc plan to 4°. All plans were initially
optimized until the planning criteria set by the RPC were met. More optimization attempts were
made to improve the homogeneity and conformity of the dose distributions. We attempted to reduce

Figure 2-5 Beam angles entering body in 3D view of nine field IMRT treatment plan
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the hot spots in the PTVs and make the dose in these structures as homogenous as possible. We
created additional structures, such as volume expansions, rings and avoidance structures, to conform
the prescription dose to the PTVs as much as possible.
The final dose for the SmartArc plan was calculated with the Adaptive Convolve dose
engine. The RapidArc and IMRT plans were calculated with the AAA dose engine. All plans were
calculated using a 4 mm calculation grid and were normalized to approximately 95% of the primary
PTV receiving 6.6 Gy. The Elekta VMAT, RapidArc, and IMRT plans had a total of 1491, 2494, and
2274 MU, respectively. The total number of MU for each arc of an individual delivery of the Elekta
VMAT and RapidArc plans were high and the treatments were splits into three and two fractions,
respectively. The dose per fraction was reduced correspondingly to achieve the full 6.6 Gy
prescription. The final treatments were delivered in three fractions of 2.2 Gy for Elekta VMAT and
two fractions of 3.3 Gy for RapidArc.

2.4

Treatment Plan Quality Comparison
We evaluated the plan quality of the two VMAT and one IMRT head and neck treatment

plans to determine if they were clinically comparable. First, we evaluated each plan’s ability to
achieve the dose objectives set by the RPC, outlined in Table 2-2. To qualitatively evaluate the
quality of each treatment plan, we generated and examined dose-volume histograms (DVH).
To compare the plans on their ability to minimize hot spots and to keep doses to normal
tissues low we recorded the maximum doses in each PTV, the OAR, and normal tissue. The
maximum dose was taken as the dose to the hottest 0.1 cc from the DVH. Additionally, the
percentage of the secondary PTV receiving its prescription dose, its PTV coverage, was compared
for all plans. The primary PTV coverage was not compared because the plans were normalized to the
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prescription dose covering 95% of the primary PTV. The secondary PTV coverage indicated the
plans ability to give adequate dose to a secondary volume while maintaining primary PTV coverage.
We quantified how well the prescription dose conformed to the primary PTV using the
conformity index (CI) expressed in equation 2-1. The CI evaluated a plan’s ability to spare normal
tissue from the high doses delivered to treatment volume. In equation 2-1, Vprescrip was the total
volume of tissue receiving the prescription dose, 6.6 Gy. VPTV was the volume of the primary PTV
structure.

CI =

V prescrip
VPTV

Eq. 2-1

Since optimal plans have uniform doses in their treatment volumes, the homogeneity of each
PTV was evaluated. We used the homogeneity index (HI), described in equation 2-2 below, to
characterize the homogeneity. D5% was the dose delivered to the hottest 5% of PTV structure and
D95% was the minimum dose received by 95% of the PTV structure, both taken from the plan’s DVH.

HI =

2.5

D5%
D95%

Eq. 2-2

Dosimetric Accuracy Evaluation
To determine if the dosimetric accuracy of the VMAT techniques was clinically acceptable,

we delivered each of the three planned treatments to the RPC IMRT head and neck phantom and
measured the dose distribution with TLDs and radiochromic film.
2.5.1

Phantom Irradiation

We delivered the Elekta VMAT plan on an Elekta Synergy® linac at Mary Bird Perkins
Cancer Center in Baton Rouge, LA. The Synergy was equipped with an MLCi2 which had 10 mm
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leaf width and forty leaves per bank. The linac was calibrated following the TG-51 protocol to 1
cGy/MU in muscle at dmax under reference conditions of 100 cm SSD and 10 cm by 10 cm field size.
We delivered the RapidArc and IMRT plans on a Varian Clinac iX linac. The MLC system
was the Varian Millennium 120 which had sixty leaves per bank. The central 40 leaves were 5 mm in
width and the peripheral leaves were 10 mm in width. The linac was calibrated following the TG-51
protocol to 1 cGy/MU in muscle at dmax under reference conditions of 100 cm SSD and 10 cm by 10
cm field size.
Prior to the delivery, we measured the machine output for 6 MV x-rays using the monthly
QA protocol of the linac’s institution. After the machine output was verified, we positioned the
phantom on the treatment table in the same manner as the simulation: head-first supine, and lined up
to the simulation isocenter indicated by the initial crosshair marks (see Figure 2-6). Then, we shifted
the couch to the treatment isocenter and drew new crosshairs on the top and sides of the phantom.
We

delivered

each

treatment

as

specified by its treatment plan and delivered all
fractions. Each irradiation of the Elekta VMAT
plan and RapidArc plan involved delivering
three and two fractions, respectively (refer to
section 2.3.4 Treatment Plans for explanation).
The treatment deliveries and measurements
were repeated three separate times. We loaded
new TLD and radiochromic films into the
phantom prior to each irradiation. Between
each irradiation, we had to remove the insert to
Figure 2-6 Photograph of phantom on treatment
table of the Varian Clinac iX linear accelerator

unload the previous treatment’s dosimeters and
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replace with new ones. The setup was confirmed prior to each irradiation and the phantom adjusted
as necessary to align the phantom to the treatment isocenter.
We performed an additional output check following a standardized RPC protocol that
involves irradiating two TLDs in 4.4 cm by 4.4 cm square blocks of PMMA under conditions
specified by the RPC. These blocks, known as mini-phantoms, were 3 cm tall with the TLDs located
in the middle at 1.5 cm depth. The field size was 10 cm by 10 cm and the source-to-surface distance
(SSD) was set to 100 cm to the top of the block. 300 MU of 6 MV photons were delivered to the
TLDs, which were at the dmax for 6
MV. The TLD block and setup are
shown in Figure 2-7.
The doses to the TLDs were
subsequently read-out by the RPC
and corrections were applied to
determine the machine output. The
purpose of this check was to
compare the machine output with
the nominal dose for 300 MU under

Figure 2-7 Setup of the RPC machine output check involving
irradiating two TLD in a Lucite block mini-phantom

reference conditions. We used this value later to correct our measurements for machine output
variations from the nominal output used to calculate dose (see section 2.5.3 Absolute Point Dose
Analysis).
All plans were delivered using the record and verify system, Mosaiq, and treated in QA
mode.
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2.5.2

Dosimeters

TLD and radiochromic film are radiation dosimeters that are used extensively by the RPC in
their credentialing process. The dosimeters measure radiation dose passively and are ideal for remote
audits where the phantom is mailed to an institution, irradiated, and then mailed back to the RPC for
analysis. In this study, TLD and radiochromic film were used to measure absolute point doses and
relative dose distributions, respectively.
2.5.2.1

Thermoluminescent Dosimetry

Thermoluminescent (TL) dosimetry is based upon the thermoluminescence process in which
light is emitted from a material upon heating. These materials, known as TL phosphors, are crystal
structures that contain imperfections, known as traps. These traps hold electrons or their holes in an
electric potential well. When the crystal is heated, these electrons and holes can recombine at
luminescence centers. When this occurs, a light photon is released. The intensity of this light
released can be measured.
Some of these TL phosphors can perform as dosimeters if the energy deposited by radiation
causes an ionization event that raises electrons to the traps. If the number of electron-hole pairs in
traps is approximately proportional to the energy deposited by radiation, then the radiation dose
received by the crystal material can be determined from the intensity of light released.
The RPC uses lithium fluoride powder doped with magnesium and titanium impurities to
provide traps, a TL phosphor, as the sensitive material in their TLD. This material is also known as
TLD-100. The sensitive part of the dosimeter is housed in a high-impact polystyrene cylindrical
capsule, 15 mm tall and 4 mm in diameter. There are two separate packets of powder in each
capsule, about 20 mg each, that yield two measurements.
The radiation dose received by the powder is determined by heating each packet of powder
individually and measuring the amount of light emitted by a photomultiplier tube. The reading is
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adjusted by several correction factors to obtain absorbed dose to muscle, D, as seen in Equation 2-3
below.

D = M ×S × E× L× F

Eq. 2-3

M is the TL response per mass of powder measured. S is the system calibration factor,
absorbed dose per system response, which is found by measuring the TL response of TLD irradiated
to known doses by Co-60 under standard conditions. E is an energy correction that is applied since
the TL material response varies with energy slightly differently than tissue. Also, L is a linearity
correction factor that is applied because the TL response is not exactly linear with dose and becomes
supra-linear at higher doses. Lastly, F, a fading correction factor is applied that is dependent on the
time elapsed from the irradiation to the reading. The reading fades at a rate that decreases
exponentially with time because the trapped electrons and holes are not completely stable. The
fading rate is dependent on the depth of the trap (energy required to excite electron sufficiently to
enable recombination). Shallower, more unstable traps fade faster. By about ten days post irradiation,
the fading becomes relatively constant (13). Therefore, the RPC waits a minimum ten days to
measure the TL response to allow the most unstable traps to recombine and reduce the uncertainty of
the measurement due to uncertainty of the exact time elapsed since irradiation.
The RPC determines the energy response, dose linearity, and fading corrections for each
batch of TLD they use. A single batch was used for this study and corresponding corrections were
applied. The TLD were all read at least 14 days post-irradiation. This TLD system has been shown to
agree with ionization chamber measurements within ±4% at a 90% confidence level (13). The
precision of the TLD measurement system is 3%.
2.5.2.2

Radiochromic Film Dosimetry

Radiochromic film is a radiation dosimeter that measures planar radiation dose distributions.
Unlike radiographic film, it is self-developing and requires no processing post-irradiation. It has
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good spatial resolution (< 0.1 mm) which makes it ideal for measuring high dose gradients (14). The
particular radiochromic film used in this study was GafChromic® EBT2 (International Specialty
Products, Wayne, NJ) which is designed for use in external beam radiation therapy applications.
EBT2 film is nearly tissue equivalent (Zeff = 6.84 according to the manufacturer) and has low
energy-dependence in the energy range of therapeutic radiation and its scatter. Its response reported
by the manufacturer is about 10% different at 60 keV from 6 MV. A more recent study has found
that the response varies only about 4.5% from energies of 75 kVp to 18 MeV (14). EBT2 is designed
for measurement of doses ranging from 1 cGy to 40 Gy.
The active component of the film is a 30 micron thick layer of material that develops a blue
polymer upon exposure to ionizing radiation. The active layer also contains a yellow dye that
reduces the light sensitivity of the film and causes the film to appear to turn dark green with
exposure. Irradiation causes the film to absorb light at 636 nm and 585 nm peaks. The reduced
transmission of light, the optical density (OD), is related to the dose received.
Three films were cut from a template for each phantom irradiation. The two sagittal films,
superior and inferior, were cut to fit into the slots in the insert and had a cutout for the OAR TLD.
The axial film was cut to the approximate shape of the insert and sandwiched between the two halves
of the insert. The films were marked along the edges to maintain the correct orientation.
The recommendations by AAPM Task Group 55 for radiochromic film handling and
dosimetry were followed in this study (15). We read all films at least 10 days post-irradiation to
allow the film to fully develop and reduce uncertainties caused by the density increase, which is
proportional to the logarithm of time. The films were kept in consistent conditions of low humidity
and room temperature and were stored in dark, light-blocking envelops. An un-exposed piece of film
was stored with each set of film to measure background radiation.
We measured the OD distribution of the EBT2 film using a transmission densitometer, the
CCD100 Microdensitometer (Photoelectron Corporation, Lexington, MA). This system consisted of
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placing the films on a light box with light-emitting diodes (LED) and measuring the light transmitted
through the films with a charge-coupled device (CCD) camera. The LEDs emissions were centered
at 665 nm, which is close to the primary absorption peak of irradiated EBT2 film. The system was
enclosed in a light-tight closet to prevent outside light contaminating the measurement. We set the
camera to the optimal focal distance from the film, based on the size of area to be measured, 150 mm
by 150 mm in the center of the densitometer, and subsequently checked the focus. Outside of this
focal area, we covered the densitometer with a black mask to block the light. The resolution of the
CCD camera was 512 by 512 pixels, resulting in pixel sizes of about 0.3 mm.
Next we imaged a blank piece of film from the same batch covering the entire imaging area.
This image was stored as a ‘flat field’ to correct for scanner variations in the subsequent readings.
Then we set a spatial calibration by imaging a 10 mm by 10 mm grid. After the scanner was
calibrated, we measured the optical densities of the experimental films, maintaining the same film
orientation during reading. We imaged the axial film by itself and the two sagittal films together,
allowing for a small separation between the superior and inferior films. The measurements were
saved as .FIT files.
To generate a dose response curve that correlated OD to radiation dose for our specific batch
of EBT2 film, we performed a calibration of the film batch. We cut nine 3 cm by 3 cm squares of
film and marked them to maintain their orientation. All film squares were placed on the center of 9
cm slabs of solid water on a linac table and covered with a 1.5 cm slab of solid water. The pieces
were oriented approximately 1 cm apart. We set a 100 cm SSD to the top of the solid water stack and
centered it in a 35 cm by 35 cm field. We then irradiated the film squares with 6 MV photons at the
dmax depth, 1.5 cm. We delivered a specified number of MU, removed a single square of film, repositioned the setup, and delivered another specified number of MU until all nine squares of film had
been irradiated to a different total number of MU. The total number of MU delivered to each square
of film can be seen below in Table 2-3. The dose delivered to each square of film was calculated by
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multiplying the total delivered MU by the output factor for a 35 cm by 35 cm field, 1.095, and are
also shown in Table 2-3. The film squares were exposed to doses ranging from 0.55 Gy to 14.78 Gy.
Table 2-3 Irradiation of EBT2 film
batch to generate a dose response
curve for film calibration

square #

Total
MU

Dose
(Gy)

1
2
3
4
5
6
7
8
9

50
150
250
350
550
750
950
1150
1350

0.55
1.64
2.74
3.83
6.02
8.21
10.40
12.59
14.78

We imaged each square of film using the same method described above and measured the
OD over a region of interest in the center of each square three times. A background square of film
that was stored with the calibration film squares was also measured and the value subtracted from the
average OD of each square. We plotted the net optical densities against the calculated dose delivered
and fit a third-order polynomial to the data (see Figure 2-8). We used the equation of the fit, equation
2-4, to convert the OD of our experimental films, x, to dose, D, in Gy. The OD of the corresponding
background film was measured and subtracted from the OD of the experimental films before
converting to dose.

D = 38.289 x 3 − 20.793 x 2 + 7.0476 x

Eq. 2-4
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Figure 2-8 Dose response curve for the batch of EBT2 film used in this study

2.5.3

Absolute Point Dose Analysis

The absolute dose delivered to each of the eight TLDs in the phantom insert was measured
using the RPC method described in 2.5.2.1
Thermoluminescent Dosimetry. The output of the machine was determined from the pairs of TLD
irradiated in the mini-phantoms during the same sessions as the head and neck phantom irradiations.
To ensure a true comparison of the calculated dose to delivered dose without the effects of machine
output variation, we normalized the measured dose to the measured machine output. We then
compared these corrected measured doses to the doses predicted by the TPS, which were the mean
doses in the TLD structures recorded from the TPS. We found the ratio of the corrected measured
dose to the TPS calculated dose for each TLD site. To comply with RPC standards, the measured
point doses of the primary PTV and secondary PTV must be within ±7% of the calculated dose; the
ratio must be within 0.93 to 1.07.

28

2.5.4

Film, Plan, and Phantom Registration

To facilitate comparing measured dose distributions to the calculation of the treatment
planning systems, the films and treatment plan data had to be registered to a single coordinate
system. We exported the plans, CT images, and dose distributions from Pinnacle and Eclipse in the
DICOM-RT format. We then imported them into the Computational Environment for Radiotherapy
Research (CERR) (J.O. Deasy and Washington University, St. Louis, MO). This software was
developed for the MATLAB® language (The MathWorks, Inc., Natick, MA) to view and analyze
treatment plans in a standard format. In this software, we were able to register the treatment plan to
the actual phantom coordinates by selecting specified points on the treatment planning CT images
that correspond to known locations in the phantom.
In an additional program developed for MATLAB, called rpcfilm, we opened the .FIT files
containing the OD information of the films. We used the holes pierced in the film, which were
visible in the film images, to register the film to the phantom coordinates of the actual pins and
converted from OD using the dose response curve we generated (see Figure 2-8). We accounted for
the OD of the background film piece.
To allow a comparison of absolute dose, the film dose was normalized to the corresponding
dose measured by the TLDs in the primary PTV. In several locations, the ratio of the TLD-measured
dose to the film-measured dose was determined. For the axial film, the average of the superior and
inferior TLD doses were used to determined the ratios of dose at the locations on the film
corresponding to the sets of anterior and posterior TLD. For the sagittal films, we determined the
ratios of the locations corresponding to all four TLDs in the primary PTV: anterior superior, anterior
inferior, posterior superior and posterior inferior. For each film plane measurement, axial or sagittal,
we used the average of its TLD/film measurement ratios to correct the film to absolute dose.
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2.5.5

Planar Dose Analysis

In the rpcfilm program, the film measurements were compared to the registered treatment
plan dose distribution. We measured profiles of the dose taken through the center of the primary
PTV in each orthogonal direction. We took the anterior-posterior and lateral profiles from the axial
film and the superior-inferior profile from the sagittal films. The film measurements were sampled at
a 0.3 mm resolution. We smoothed the profiles by using a moving average over eleven data points,
or 3 mm. We visually compared the film profiles to the treatment plan calculated profiles to
determine if any major shifts from the planned setup had occurred.
The dose fall-off between the posterior edge of the primary PTV and the anterior edge of the
OAR was evaluated based on DTA. We performed a linear regression of the penumbra on the
smoothed anterior-posterior profile from the axial film and of the penumbra of the corresponding
treatment plan profile. We evaluated three points along each linear regression at 25%, 50% and 75%
of the difference between the maximum and minimum dose levels. The maximum and minimum
doses were taken as the average of a relatively flat region in the primary PTV and in the OAR,
respectively. The distance between these doses along the measured and calculated dose profile was
measured. We calculated the average value of these three distances for each treatment delivery for
each treatment type and compared it to the RPC acceptability criterion: 4 mm for the penumbra
between the primary PTV and the OAR.
The planar doses measured were also compared to the TPS calculated doses in rpcfilm using
gamma analysis as described by Low, et al (16). We used this test to evaluate how well our measured
and calculated dose distributions agree. First, we used acceptability criteria of ±5% dose difference
and 3 mm DTA with 95% of the points passing being clinically acceptable. These criteria are the
typical values used by the RPC for IMRT credentialing with anthropomorphic phantoms and are
common clinical criteria, as well. However, the RPC currently does not include gamma analysis in
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credentialing for head and neck IMRT. We evaluated an area covering both PTVs and the OAR in
both the axial and sagittal planes, shown in Figure 2-9 and Figure 2-10, respectively.

Figure 2-9 Area in axial plane where gamma analysis
was performed with 5% dose difference and 3 mm
DTA criteria

Figure 2-10 Area in sagittal plane where
gamma analysis was performed with
5% dose difference and 3 mm DTA
criteria

Although the RPC does not use gamma analysis for their head and neck IMRT credentialing,
they have been collecting data using a ±7% dose difference and 4 mm DTA criteria over a region
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defined in the axial plane, shown in Figure 2-11. Therefore, we performed a second gamma analysis
using ±7% dose difference and 4 mm DTA criteria in a region around the primary PTV in the axial
plane. We compared the percent of points passing with data collected from 452 institutions that have

Figure 2-11 Area in axial plane where
gamma analysis was performed with 7%
dose difference and 4 mm DTA criteria

undergone the RPC credentialing process for head and neck IMRT.
2.5.5.1

Gamma Analysis

Gamma analysis is a quantitative evaluation of how well two dose distributions agree (16). It
incorporates two different criteria to evaluate the agreement of two dose distributions into a single
value, the γ-index. The criteria compare points based on the dose difference between the two
distributions at a point and the distance to a point in the other distribution of the same dose (distanceto-agreement, DTA). This analysis involves setting the acceptable dose difference and DTA criteria
and determining how many points are in agreement.
The purpose of using two measures to evaluate how well dose distributions agree is to
provide for high and low dose gradients. In high dose gradients, the dose is changing rapidly from
point to point, and small spatial errors may cause large differences in dose. However, the distance
between two points of the same dose may be small. In low dose gradient regions, where the dose is
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more homogenous, small discrepancies in dose value may cause the distance between two points of
the same dose to be very far away, even if the difference in dose from nearby points is small.
The first step in gamma analysis is determining the value of Γ(rm , rc ) for every measurement
and calculation point, which is described by equation 2-5 below, where rm is a single measurement
point, and rc is a spatial point in the calculated dose distribution. Δd m is the preset DTA criterion
and ΔDm is the preset dose difference criterion.

Γ(rm , rc ) =

r 2 (rm , rc )
Δd m

2

+

δ 2 (rm , rc )
ΔDm

2

Eq. 2-5

where,

r (rm , rc ) = rm − rc , the DTA and

δ (rm , rc ) = Dc (rc ) − Dm (rm ) , the dose difference
Γ(rm , rc ) forms an ellipse when it is set equal to one with the major axes being DTA,
r (rm , rc ) , and dose difference, δ (rm , rc ) . A Γ(rm , rc ) of less than or equal to one passes the
acceptance criteria set. The γ-index is the minimum value of the term, Γ(rm , rc ) , for a single
measurement point, rm . If the γ-index is less than or equal to one, then that point in the measured
dose distribution passes the acceptance criteria. The γ-index can be found for every point in a
measured distribution and the total percent of points passing can be determined (16).
The software rpcfilm, which we used to perform gamma analyses, has a tool to mask certain
areas of the film image. This was used to exclude areas beyond the film edge and the pin prick marks
that were included in the evaluation areas. The mask nullifies the area in the gamma analysis, not
counting it as passing or failing.

33

2.5.6

MLC Log File Analysis

In order to better understand patterns we found in the results, we recorded the dynalog files
for repeated deliveries of the RapidArc plan. The dynalog files are Varian’s MLC log files and
record the error in the MLC position, counted every 50 milliseconds, relative to the expected MLC
position as defined by the treatment plan. The errors are reported in two ways. The first is the root
mean square (RMS) of the deviation of each leaf over the whole treatment. The other is a histogram
of the magnitude of the errors of each count. The files were recorded separately for five deliveries of
each arc and the variation of the RMS leaf deviation was evaluated for the repeated deliveries of the
RapidArc plan.
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Chapter 3
3.1

Results

Treatment Plan Quality Comparison
To determine the TPS ability to generate treatment plans that can achieve typical

prescriptions and constraints for the RPC head and neck phantom, each plan was evaluated on its
ability to meet the RPC constraints, which were presented in Table 2-2. The results of this analysis
are shown below in Table 3-1.
Table 3-1 The values of each dosimetric objective for all three treatment plans, including
prescriptions and dose constraints

Structure

Dosimetric Criteria

Elekta VMAT

RapidArc

IMRT

D95% ≥ 6.60 Gy

6.58 Gy

6.60 Gy

6.59 Gy

D99% ≥ 6.14 Gy

6.37 Gy

6.35 Gy

6.42 Gy

D95% ≥ 5.40 Gy

5.43 Gy

5.43 Gy

5.41 Gy

D99% ≥ 5.03 Gy

5.40 Gy

5.28 Gy

5.32 Gy

Normal tissue

max dose ≤ 7.26 Gy

6.76 Gy

6.89 Gy

6.82 Gy

Organ at risk

max dose < 4.5 Gy

4.14 Gy

4.09 Gy

4.10 Gy

Primary PTV

Secondary PTV

The data in the first row of Table 3-1 defines the prescription for the primary target volume.
The treatment plans were normalized to meet this objective (6.6 Gy to 95% of the primary PTV
volume). However, the actual values of primary PTV coverage resulting from the normalization are
slightly less than 6.60 Gy for 95% of the primary PTV volume. Since this is a result of the treatment
plan normalization, it was not considered in the analysis of each plan’s ability to comply with the
RPC dose objectives. All plans passed all of the other dosimetric criteria.
Next, we qualitatively compared the DVHs of the three different treatment plans. The DVHs
are shown in Figure 3-1. The slopes of the DVHs of both PTVs for the Elekta VMAT plans are
steeper than the other plans, indicating more uniform PTV dose. The RapidArc plan had slightly less
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Figure 3-1 DVHs of the primary PTV (blue), secondary PTV (green), OAR (red), and normal tissue
(brown) for the Elekta VMAT (solid), RapidArc (dotted), and IMRT (dashed) treatment plans

steep dose than the IMRT plan, as well. However, the normal tissue dose was generally higher for
the Elekta VMAT plan in comparison to the RapidArc and IMRT plans.
The maximum doses in both PTVs, the OAR and the normal tissue were compared to see
how well the treatment plans could reduce the magnitude of the hot spots. The maximum doses for
each plan are reported in Table 3-2. The hot spots in the PTVs were lowest for the Elekta VMAT
plan. The maximum doses of the OAR and normal tissue were similar for all plans.

Table 3-2 Maximum dose to the primary PTV, secondary PTV, OAR, and normal tissue
structures with the percent of the prescription dose for each PTV shown in parenthesis

Structure

Elekta VMAT

RapidArc

IMRT

Primary PTV

688 cGy (104%)

719 cGy (109%)

714 cGy (108%)

Secondary PTV

553 cGy (102%)

587 cGy (109%)

581 cGy (108%)

OAR

4.14 Gy

4.09 Gy

4.10 Gy

Normal tissue

6.76 Gy

6.89 Gy

6.82 Gy
36

The percentage of each treatment volume covered by the prescription dose for the secondary
PTV was determined for all treatment plans. The values obtained for the Elekta VMAT, RapidArc,
and IMRT plans were 99.2%, 96.0%, and 95.7%, respectively. The Elekta VMAT plan was able to
achieve greater prescription dose coverage of the secondary PTV.
The conformity index (CI) was calculated using equation 2-1 for the primary PTV for all
treatment plans. Generally, lower values of CI indicate better conformity and a perfectly conformal
dose would have a CI of 0.95. The resulting CI were 1.08, 1.02, and 1.01 for the Elekta VMAT,
RapidArc, and IMRT plans respectively. The Elekta VMAT treatment plan had the highest CI,
indicating that it had a less conformal dose distribution than the RapidArc and IMRT treatment
plans. This is consistent with the higher normal tissue doses seen in the DVH of the Elekta VMAT
treatment (brown solid line) in Figure 3-1.
The homogeneity index (HI) was calculated using equation 2-2 for both the primary and
secondary PTVs for all treatment plans. Lower values of HI indicate more uniform dose in the
treatment volumes. The results are reported in Table 3-3. The RapidArc and IMRT treatment plans
had the highest HI, indicating that those plans had less uniform dose in the treatment volumes. These
results are consistent with the DVHs shown in Figure 3-1, where the slopes of the primary and
secondary PTV DVHs (blue and green solid lines, respectively) are steepest for the Elekta VMAT
plan.
Table 3-3 Homogeneity indices (HI) of both PTVs calculated for all three treatment plans

Structure

Elekta VMAT

RapidArc

IMRT

Primary PTV

1.04

1.08

1.07

Secondary PTV

1.02

1.07

1.06

Isodose distributions for all three treatment plans can be found in the Appendix in Figure
5-1, Figure 5-2, Figure 5-3.
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3.2

Dosimetric Accuracy Evaluation

3.2.1

Absolute Point Dose Analysis

The doses at eight locations in the phantom were measured using TLD capsules. All of the
actual dose values measured are reported in the in Table 3-4 for the Elekta VMAT treatment, Table
3-5 for the RapidArc treatment, and Table 3-6 for the IMRT treatment. The doses are listed in cGy
for each TLD measurement for each treatment delivery. The average and percent standard deviation
of the three deliveries are also shown. Each measurement point is identified by the position of the
TLD in the phantom. The TLD position is described by the structure the TLD it is located within and
its placement within that structure (superior versus inferior and, when applicable, anterior versus
posterior). The greatest percent standard deviation of TLD measurements at a single point for the
Elekta VMAT, RapidArc, and IMRT treatments were 1.22%, 1.45%, 1.82%, respectively. At most
measurement locations the percent standard deviation is less than 1% indicating that there is little
variation in the TLD measurements across treatment deliveries. Table 3-7 shows the mean dose
calculated for each TLD structure by the TPS for each plan.
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Table 3-4 Doses measured by eight TLD in the phantom insert for three deliveries of the Elekta VMAT
treatment

TLD position
Primary PTV
Superior Anterior
Primary PTV
Inferior Anterior
Primary PTV
Superior Posterior
Primary PTV
Inferior Posterior
Secondary PTV
Superior
Secondary PTV
Inferior
OAR
Superior
OAR
Interior

1

Delivery
2

3

644

644

643

Average

Percent standard
deviation

647

645

0.27%

650

646

646

0.51%

635

641

647

641

0.89%

643

641

649

644

0.72%

527

534

525

528

0.88%

517

527

529

524

1.22%

259

261

260

260

0.48%

253

257

256

256

0.78%
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Table 3-5 Doses measured by eight TLD in the phantom insert for three deliveries of the RapidArc
treatment

TLD position
Primary PTV
Superior Anterior
Primary PTV
Inferior Anterior
Primary PTV
Superior Posterior
Primary PTV
Inferior Posterior
Secondary PTV
Superior
Secondary PTV
Inferior
OAR
Superior
OAR
Interior

1

Delivery
2

3

724

737

745

Average

Percent standard
deviation

737

732

1.01%

742

736

741

0.68%

728

734

738

733

0.71%

735

744

751

744

1.08%

591

604

608

601

1.45%

621

622

622

622

0.04%

357

357

358

357

0.06%

355

361

362

359

1.01%
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Table 3-6 Doses measured by eight TLD in the phantom insert for three deliveries of the IMRT
treatment

TLD position
Primary PTV
Superior Anterior
Primary PTV
Inferior Anterior
Primary PTV
Superior Posterior
Primary PTV
Inferior Posterior
Secondary PTV
Superior
Secondary PTV
Inferior
OAR
Superior
OAR
Interior

1

Delivery
2

3

704

715

711

Average

Percent standard
deviation

708

709

0.73%

704

708

708

0.48%

714

713

719

715

0.49%

713

708

714

712

0.41%

599

598

590

596

0.89%

599

590

591

593

0.87%

299

295

306

300

1.82%

301

293

300

298

1.50%
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Table 3-7 Treatment planning system calculation of the mean dose at
eight TLD locations within the phantom insert

Elekta
VMAT

RapidArc

IMRT

Primary PTV
Superior Anterior

671

694

689

Primary PTV
Inferior Anterior

671

700

690

Primary PTV
Superior Posterior

677

697

685

Primary PTV
Inferior Posterior

681

701

689

Secondary PTV
Superior

550

575

569

Secondary PTV
Inferior

551

578

569

OAR
Superior

321

346

306

OAR
Interior

317

353

302

TLD position

The ratios of the measured TLD dose to the calculated dose of the corresponding TLD
structure in the TPS are reported in Table 3-8, Table 3-9, and Table 3-10 for the Elekta VMAT,
RapidArc, and IMRT treatments, respectively. The six measurement points in the PTVs were
evaluated to determine if they met the RPC absolute dose criterion of ±7%. The dose of the OAR is
not included in this analysis since it is generally a steep dose gradient and small errors in position
may cause larger errors in dose.
The ratios at these six locations in the phantom are within 0.93 to 1.07 for all three deliveries
of all three treatment plans and, therefore, pass the RPC criterion. In the PTVs, where the dose is
relatively uniform, the IMRT treatment had the best agreement, and the RapidArc treatment had the
worst agreement. However, in the OAR, where there is a steep dose gradient, the RapidArc treatment
had the best agreement, and the Elekta VMAT had the worst agreement. Also, the Elekta VMAT
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treatment plans consistently underestimated the dose while the RapidArc and IMRT treatment plans
mostly overestimated the dose, with the exceptions occurring in the OAR dose.

Table 3-8 Ratio of the measured TLD dose to the calculated TPS dose at
eight locations in the phantom for three deliveries of the Elekta VMAT plan

TLD position
Primary PTV
Superior Anterior
Primary PTV
Inferior Anterior
Primary PTV
Superior Posterior
Primary PTV
Inferior Posterior
Secondary PTV
Superior
Secondary PTV
Inferior
OAR
Superior
OAR
Interior

1

Delivery
2

3

0.97

0.97

0.98

0.98

0.97

0.98

0.98

0.98

0.95

0.96

0.97

0.96

0.96

0.95

0.97

0.96

0.97

0.98

0.97

0.98

0.95

0.97

0.97

0.97

0.82

0.83

0.82

0.82

0.81

0.82

0.82

0.82

Average
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Table 3-9 Ratio of the measured TLD dose to the calculated TPS dose at
eight locations in the phantom for three deliveries of the RapidArc plan

TLD position
Primary PTV
Superior Anterior
Primary PTV
Inferior Anterior
Primary PTV
Superior Posterior
Primary PTV
Inferior Posterior
Secondary PTV
Superior
Secondary PTV
Inferior
OAR
Superior
OAR
Interior

1

Delivery
2

3

1.02

1.04

1.04

1.03

1.04

1.04

1.03

1.04

1.02

1.03

1.04

1.03

1.03

1.04

1.05

1.04

1.01

1.03

1.03

1.02

1.05

1.05

1.05

1.05

1.01

1.01

1.01

1.01

0.99

1.00

1.00

1.00

Average
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Table 3-10 Ratio of the measured TLD dose to the calculated TPS dose at
eight locations in the phantom for three deliveries of the IMRT plan

TLD position
Primary PTV
Superior Anterior
Primary PTV
Inferior Anterior
Primary PTV
Superior Posterior
Primary PTV
Inferior Posterior
Secondary PTV
Superior
Secondary PTV
Inferior
OAR
Superior
OAR
Interior

1

Delivery
2

3

1.00

1.02

1.01

1.01

1.01

1.00

1.00

1.00

1.02

1.02

1.03

1.02

1.01

1.01

1.01

1.01

1.03

1.03

1.01

1.02

1.03

1.01

1.02

1.02

0.96

0.95

0.98

0.96

0.98

0.95

0.97

0.97

Average
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3.2.2

Planar Dose Analysis

3.2.2.1

Dose profile comparison

The measured and calculated dose profiles for the Elekta VMAT, RapidArc, and IMRT
treatments are reported in Figure 3-2 through Figure 3-4 and in the Appendix in Figure 5-4 through
Figure 5-9. Figure 3-2 through Figure 3-4 show the lateral profiles taken from the axial film through
the center of the primary PTV. Figure 5-4 through Figure 5-9 show the posterior-to-anterior profile
measured from the axial film and the inferior-to-superior profile measured from the sagittal films,
both through the center of the primary PTV. In each figure, the corresponding calculation is shown
along with the measurements of all three treatment deliveries of each plan.
In general, the measured dose profiles were lower than calculation for the Elekta VMAT
treatment deliveries (Figure 3-2, Figure 5-4, and Figure 5-5), which corresponds with the TLD
measurements where the ratios of measured to calculated doses was less than one. For the RapidArc
(Figure 3-3, Figure 5-6, and Figure 5-7) and IMRT treatments (Figure 3-4, Figure 5-8, and Figure
5-9), the measured dose profiles were greater than calculation. This trend was also seen in the TLD
measurement to calculation ratios, which were mostly greater than one for both the RapidArc and
IMRT treatment deliveries. All treatments had difficulty with the posterior-to-anterior dose profile in
the region of the dose falloff between the primary PTV and the OAR. The Elekta VMAT had the
greatest deviation between the measured and calculated penumbra in this region (Figure 5-4). This
corresponds with the large difference between the measured TLD dose in the OAR and calculation
for the Elekta VMAT treatment, as shown in Table 3-8. The gap in the measurements shown in the
inferior-to-superior dose profiles (Figure 5-5, Figure 5-7, and Figure 5-9) corresponds to the location
of the gap between the two sagittal films used to measure these profiles.
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Figure 3-2 Lateral dose profile of the Elekta VMAT treatment
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Figure 3-3 Lateral profile of the RapidArc treatment
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Figure 3-4 Lateral dose profile of the IMRT treatment

The results of the displacement of the measured posterior penumbra from calculation are
shown in Table 3-11 in millimeters for all treatment deliveries. All deliveries met the 4 mm DTA
criterion specified by the RPC. The displacement of the penumbra measured from the Elekta VMAT
treatments is by far the largest, which corresponds with the large deviation seen in the posterior-toanterior dose profile measured (Figure 5-4). The displacement of the RapidArc and IMRT treatments
was no more than 2.0 mm in all cases.
Table 3-11 Displacement (mm) of measurement from calculation of the
posterior penumbra between the primary PTV and the OAR

Treatment
Elekta VMAT
RapidArc
IMRT

3.2.2.2

Delivery
1

2

3

3.4
1.2
2.0

3.5
1.3
1.9

3.2
1.7
1.5

Average
3.4
1.4
1.8

Gamma analysis

The agreement of the axial and sagittal film measurements to the corresponding treatment
plans was evaluated using gamma analysis. The spatial distribution of the gamma analyses’ results
for all treatments and deliveries are shown in Figure 5-10 through Figure 5-27 in the Appendix, and
representative examples are shown here in Figure 3-5 through Figure 3-13. The gamma analyses
shown in these figures did not use the masking feature and, therefore, the entire area, including the
areas off the film edge, was included in the analyses shown. Consequently, the results of the gamma
analysis reported in the figures represent artificially lower percent of points passing.
The first evaluation used acceptability criteria of ±5% dose difference and 3 mm DTA in
both the axial and the sagittal planes. The resulting percent of points passing with masking used per
treatment delivery are reported in Table 3-12. The average percent of points passing for each plane
evaluated for each treatment technique are shown in the table, as well. The IMRT treatment had the
highest average percent of points passing (85.7% and 85.4% in the axial and sagittal planes,
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Table 3-12 Percent of points passing gamma analysis with acceptability criteria of
5% dose difference and 3 mm DTA in the axial and sagittal planes bisecting the
primary PTV

Treatment
Elekta VMAT
RapidArc
IMRT

Film plane

Delivery

Average

1

2

3

axial
sagittal
axial
sagittal
axial

70.6%
76.1%
84.5%
82.2%
80.1%

74.2%
76.6%
80.7%
68.7%
86.9%

84.0%
79.0%
74.8%
75.2%
90.0%

76.2%
77.2%
80.0%
75.4%
85.7%

sagittal

84.4%

88.5%

83.2%

85.4%

respectively) and the Elekta VMAT treatment had the lowest average percent of points passing in the
axial plane (76.2%) while the RapidArc treatment had the lowest average percent of points passing
in the sagittal plane (75.4%). We also noted greater variation between deliveries of the Elekta
VMAT and RapidArc plans than the IMRT plan. The Elekta VMAT results ranged from 70.6% to
84.0% and the RapidArc results ranged from 68.7% to 84.5%, while the range of percent passing for
the IMRT treatment was 80.1% to 90.0%.
Figure 3-5 through Figure 3-10 show the axial and sagittal film results of one delivery of
each treatment technique. Most plans failed in regions of sharp dose falloff, such as in the region
between the primary PTV and the OAR. Some plans also had difficulties meeting the acceptability
criteria in the high dose regions inside the primary PTV.
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Figure 3-5 Axial gamma analysis (5%/3mm) of third Elekta VMAT treatment delivery
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Figure 3-6 Sagittal gamma analysis (5%/3mm) of third Elekta VMAT treatment delivery
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Figure 3-7 Axial gamma analysis (5%/3mm) of first RapidArc treatment delivery
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Figure 3-8 Sagittal gamma analysis (5%/3mm) of first RapidArc treatment delivery
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Figure 3-9 Axial gamma analysis (5%/3mm) of second IMRT treatment delivery
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Figure 3-10 Sagittal gamma analysis (5%/3mm) of second IMRT treatment delivery
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The second gamma analysis used acceptability criteria of ±7% dose difference and 4 mm
DTA. The results are reported in Table 3-13. These values were compared with data collected by the
RPC. As of May 27, 2010, the average percent of points passing gamma analysis was 87% for all
452 institutions evaluated and 93% for the 365 institutions that were successfully credentialed by the
RPC (17). The results of most irradiations of each treatment compare favorably with the national
average. Only the first delivery of the Elekta VMAT treatment was lower than the national average.
Only the IMRT treatment had all deliveries performing better than the national average of
institutions successfully credentialed.
Table 3-13 Percent of points passing gamma analysis with
acceptability criteria of 7% dose difference and 4 mm DTA in
the axial plane bisecting the primary PTV

Treatment
Elekta VMAT
RapidArc
IMRT

Delivery
1

2

3

83.7%
91.5%
94.2%

89.4%
91.0%
96.9%

92.1%
87.3%
98.0%

Average
88.4%
89.9%
96.4%

For the less stringent acceptability criteria, the percent of points passing the gamma analysis
improved for all treatment deliveries. The IMRT treatments still had the highest average percent of
points passing at 96.4%, while the Elekta VMAT and RapidArc had the lowest at 88.4% and 89.9%,
respectively. The Elekta VMAT treatment still exhibited large variations between deliveries with the
less stringent acceptability criteria.
Representative examples of the spatial distribution of the gamma analyses for one delivery
of each treatment technique can be seen in Figure 3-11 through Figure 3-13. For the ±7% dose
difference and 4 mm DTA acceptability criteria, the regions that failed were mostly concentrated in
the steep dose gradient between the primary PTV and the OAR, with some areas around the
periphery of the primary PTV still having difficulty.
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Figure 3-11 Axial gamma analysis (7%/4mm) of third Elekta VMAT treatment delivery
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Figure 3-12 Axial gamma analysis (7%/4mm) of first RapidArc treatment delivery
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Figure 3-13 Axial gamma analysis (7%/4mm) of third IMRT treatment delivery
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3.2.3

MLC Log File Analysis

The MLC dynalog files for repeated RapidArc deliveries were analyzed to explore the
variation in the gamma analysis results across five treatment deliveries of the same plan. Table 3-14
and Table 3-15 show the minimum, maximum, and range of the RMS values of each moving leaf for
the five treatment deliveries. Table 3-14 shows the results of the first, clockwise arc, and Table 3-15
shows the second, counterclockwise arc. Only the results of the moving leaves are shown, which
included the central sixteen leaves. The RMS values of leaf deviation for the peripheral leaves were
zero. The results of each carriage are shown separately.

Table 3-14 The minimum, maximum, and range of the RMS values of leaf deviation (cm)
for each moving leaf of both carriages for five deliveries of the first, clockwise arc of the
RapidArc treatment

Carriage A

Carriage B

Leaf

Minimum

Maximum

Range

Minimum

Maximum

Range

23

0.026

0.027

0.001

0.024

0.024

0

24

0.043

0.044

0.001

0.041

0.041

0

25

0.051

0.051

0

0.038

0.038

0

26

0.043

0.043

0

0.041

0.041

0

27

0.046

0.047

0.001

0.043

0.044

0.001

28

0.044

0.044

0

0.037

0.037

0

29

0.043

0.044

0.001

0.038

0.038

0

30

0.043

0.043

0

0.046

0.046

0

31

0.046

0.046

0

0.051

0.051

0

32

0.036

0.037

0.001

0.044

0.045

0.001

33

0.035

0.035

0

0.04

0.041

0.001

34

0.038

0.038

0

0.047

0.048

0.001

35

0.04

0.041

0.001

0.052

0.052

0

36

0.031

0.031

0

0.045

0.045

0

37

0.031

0.031

0

0.043

0.043

0

38

0.023

0.024

0.001

0.023

0.024

0.001
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Table 3-15 The minimum, maximum, and range of the RMS values of leaf deviation (cm)
for each moving leaf of both carriages for five deliveries of the second, counterclockwise
arc of the RapidArc treatment

Carriage A

Carriage B

Leaf

Minimum

Maximum

Range

Minimum

Maximum

Range

23

0.021

0.022

0.001

0.024

0.024

0

24

0.036

0.037

0.001

0.051

0.051

0

25

0.035

0.035

0

0.044

0.044

0

26

0.041

0.041

0

0.051

0.051

0

27

0.048

0.048

0

0.051

0.051

0

28

0.043

0.043

0

0.052

0.052

0

29

0.049

0.049

0

0.056

0.057

0.001

30

0.043

0.043

0

0.047

0.048

0.001

31

0.049

0.049

0

0.04

0.04

0

32

0.044

0.044

0

0.048

0.049

0.001

33

0.046

0.046

0

0.04

0.041

0.001

34

0.051

0.051

0

0.031

0.032

0.001

35

0.046

0.046

0

0.034

0.034

0

36

0.047

0.047

0

0.032

0.032

0

37

0.041

0.042

0.001

0.03

0.031

0.001

38

0.028

0.028

0

0.026

0.027

0.001

The RMS values of the individual leaf variation remained mostly constant across all
deliveries. The RMS leaf deviation varied at most 0.01 mm across all deliveries. The RMS values of
leaf deviation for the moving leaves for each treatment delivery are shown in the Appendix in Table
5-1 and Table 5-2.
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Chapter 4
4.1

Discussion

General Discussion
Our results indicate that the two VMAT techniques evaluated in this study have the ability to

generate plans of comparable quality as IMRT while delivering the calculated dose distributions
within acceptable tolerances for complex treatments, such as head and neck radiotherapy. Clinics
may chose to use these VMAT techniques in lieu of IMRT for various treatment sites in order to
reduce the total time of treatment for the patient and potentially reduce the MU necessary for some
treatment sites (4-7). However, each clinic should make treatment decisions based on their specific
requirements and should perform their own thorough QA of whichever treatment technique they
choose. Also, because of the differences in the TPS, thorough treatment planning studies should be
conducted to determine what treatment is best for their specific clinic and even for specific patient
cases.
In treatment planning studies, it is important to remember that they are not entirely objective.
The results are influenced by several factors, including the abilities of the person planning
treatments, the techniques used, the treatment site and geometry, and the time spent on a plan. As a
result, plans of varying quality can be generated for the same patient using the same treatment
planning system. These subjectivities of treatment planning confound the investigation of TPS
performance.
Although treatment planning studies are partially subjective, the treatment planning
differences in conformity and uniformity seen between the plans may be attributed to the planning
objectives available in each TPS. In Pinnacle3, where the dose distribution was more uniform in the
treatment volumes, the target dose objectives can be set to achieve uniform dose at a specified
prescription. In Eclipse, there is no uniform dose objective, just a minimum dose objective. In order
to increase the uniformity of the target dose, a maximum dose objective can be specified. Eclipse
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also has a normal tissue objective which attempts to improve the dose falloff from the target volume,
but Pinnacle3 does not. These differences in dose objective specification may explain the tradeoff
between uniformity and conformity in the treatment plans produced by Pinnacle3 and Eclipse,
respectively; however, this needs to be verified through further testing.
As for the dosimetric accuracy results, the measured doses delivered by the Elekta VMAT
and RapidArc techniques were consistent with the calculated doses, however the IMRT
measurements corresponded to their calculation better overall. The DTA agreement of the posterior
penumbra of the primary PTV as measured from the film was greater for the Elekta VMAT
treatment. Also, the percent of points passing the gamma analysis was lower for both the Elekta
VMAT and RapidArc treatments. Additionally, there appeared to be greater variation between
treatments in the results of the gamma analyses at the ±5% dose difference and 3 mm DTA level.
The simultaneous gantry rotation with varying speeds and dynamic MLC motion may be the cause of
the reduced agreement. Although the MLC deviations did not seem to vary between treatments, the
additional uncertainty of the gantry position, gantry rotation speed and MLC positions are
compounded in VMAT treatments and could be the cause of the differences in the dose delivery
from treatment to treatment. The plans evaluated in this study involved a high degree of modulation,
which may have caused the linacs to utilize more MLC motion and gantry rotation speed variation
than plans with less modulation. The effects of these complex motions and their uncertainties need to
be fully understood for QA and should be further investigated.
The literature, for the most part, is in agreement with the findings of these studies. Several
planning studies have been conducted for VMAT techniques utilizing two arcs and found that they
were equivalent to IMRT. One study by Rao, et al. has found that Elekta VMAT planned with
Pinnacle3 SmartArc generated plans that were comparable in target coverage and critical structure
sparing to IMRT for six prostate and six head and neck patient cases (7). A study by Verbakel, et al.
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has concluded that RapidArc was similar to seven field sliding window IMRT for twelve head and
neck treatments that, like our study, had a primary and secondary PTV prescription (6). They found
that the sparing of the OAR was similar, but that the RapidArc plans were significantly less
conformal. In their study, they used an older version of Eclipse that could not simultaneously
optimize two arcs, which could explain why our results found consistent conformality between
RapidArc and IMRT.
One study found that RapidArc performed better than both five and nine field sliding
window IMRT (4). In this study by Oliver, et al. that investigated virtual phantoms of varying
geometries, they found that the RapidArc plans had better conformity and uniformity and were better
able to meet the dose objectives than the IMRT plans. As mentioned before, planning studies are
subjective and this could explain the different findings.
As for dosimetric accuracy, the literature has found consistently that the accuracy of VMAT
treatments is clinically acceptable. In studies of Elekta VMAT, it was found in two separate studies
that greater than 95% of points passed gamma analysis with criteria of 3% dose difference and 3 mm
DTA (5, 7). The study by Bedford and Warrington investigated prostate and lung plans using a diode
array. However, they planned their treatment using in-house TPS and transferred the plans to be
calculated in Pinnacle3 (5). Rao, et al. evaluated prostate and head and neck cases with a twodimensional ion chamber array and, similarly to this study, planned their treatments with Pinnacle3
SmartArc (7).
RapidArc accuracy was evaluated in a Monte Carlo study by Gagne, et al. and found to be
adequate for clinical use when a 2.5 mm grid was used to calculate dose in Eclipse (8). Two
additional studies used measurement to verify RapidArc delivery (6, 9). In one, Korreman, et al.
found that greater than 95% of points passed 3% dose difference and 3 mm DTA criteria when
prostate and head and neck treatments were measured with a diode array calibrated to an ion
chamber (9). The other study by Verbakel, et al. used EBT films to measure the dose of a head and
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neck plan in several coronal planes and found that greater than 99% of the points passed a gamma
analysis with 3% dose difference and 2 mm DTA criteria (6). In fact, both of these studies found that
RapidArc performed better than IMRT.
The literature agrees with the conclusions of this study that the accuracy of VMAT
techniques is acceptable. However, each study using gamma analysis has found a higher percent of
points passing for stricter criteria (3% dose difference and 3 mm DTA or less). Also, some studies
found, upon comparison with IMRT, that RapidArc performed better. There may be several
explanations for this discrepancy. The simplest is that plans that are more challenging may affect the
accuracy of treatment techniques differently. For example, in order to deliver the degree of
modulation of dose necessary for more complex plans, VMAT treatments may need to utilize more
gantry rotation speed variation. This variation may add additional uncertainty to the treatment. An
IMRT plan would only need to increase the MU and number of segments at a static gantry angle.
Furthermore, the actual behavior of the linac rotation may vary from what the TPS expects in order
to deliver the plan. The plans in this study were very complex with a high degree of modulation and
may yield different results for different treatment techniques.
Other reasons for the discrepancy may involve the technique of measurement. For studies
involving an ion chamber or diode array, the spatial resolution is limited (5, 7, 9). In order to perform
a gamma analysis, they must interpolate between measurement points, which can affect the results.
For example, two studies used the Delta4 phantom, which has a spatial resolution of 5 mm in the
central 6 cm by 6 cm area and 10 mm at the periphery (5, 9).
In another example, the ion chamber array used in the study by Rao, et al. had a spatial
resolution of 7.6 mm and measurements were linearly interpolated to 1 mm spatial resolution.
Measurements in this study were analyzing at a 3 mm DTA criterion. They noted that film
measurements would be able to detect a greater degree of modulation (7). Ion chamber arrays have a
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volume averaging affect that can smooth the measurements, as well. The volume of the chamber in
the MatriXX array used in this study was 0.08 cm3 (7).
Our analysis used EBT2 film that was not smoothed before performing the gamma analysis.
The inherent noise of these measurements may have affected the accuracy. Also, this technique has a
much higher spatial resolution and does not need to interpolate measurements. Therefore, it can
detect greater dose modulation.
The normalization technique used in each study may also affect the accuracy found. Many
studies do not mention how they calibrate or normalize their measurements. Film is known to be a
less accurate method of dosimetry and is often used for relative dose accuracy evaluation. In this
study, we normalized our film measurements to TLD measurements, following RPC protocol.
Absolute measurements, like ours, are more strenuous. In the study by Verbakel, et al., they used two
pieces of EBT film in each measurement plane. This technique can be used to reduce the uncertainty
of inhomogenous film construction (18). However, they did not mention their normalization
technique, nor if they smoothed their film before comparing it to the treatment plan (6). For these
reasons, it makes it difficult to compare the results of different QA measurement techniques.
Our study followed the RPC protocol to determine if the plans were delivered within
acceptable accuracy tolerances. This well established protocol assesses absolute dose measurements
and has been used for years to evaluate institutions internationally. Additionally, it evaluates the
VMAT techniques in an extreme situation. The plans evaluated were very complex with steep dose
gradients and multiple target volumes with different prescriptions. Also, it was the first study to
compare different VMAT techniques head to head and offered new insight in how they perform in
similar situations. The VMAT techniques we chose to evaluate involved linacs, the Varian Clinac iX
and Elekta Synergy, and TPS, Pinnacle3 and Eclipse, that are established and prevalent in the US.
Although this study has many strengths, there are a few limitations. The plans were
generated for a phantom simulating real head and neck geometry. However, human anatomy is more
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complex and diverse. This study has shown that VMAT techniques can develop plans of IMRT
quality, but they may not always do so in all patient cases. Additionally, this was only a planning
study and cannot fully predict patient outcomes. Prospective clinical trials are needed to determine if
the effects of treatments are actually the same when VMAT is used in place of IMRT.
Overall, this study has contributed to the body of knowledge on the treatment planning
capabilities of two VMAT techniques and, for the first time, has compared them. Clinicians now
have more information to decide if VMAT is an appropriate treatment for their patients. It may be
used to help reduce the discomfort of long treatment times and help increase throughput in a clinic
(4-7). Additionally, it assures them that the treatments can be delivered with acceptable accuracy.

4.2

Conclusion
In conclusion, our hypothesis that the VMAT techniques evaluated would generate plans of

comparable quality to IMRT and accurately deliver the calculated dose for complex head and neck
treatments was supported by the results. All treatment plans performed similarly across all metrics
used to evaluate treatment plan quality with the exception of a tradeoff between dose conformity to
and uniformity in the treatment volumes. The Elekta VMAT treatment, planned with Pinnacle3 Smart
Arc, had more uniform target dose but less conformal plans than the RapidArc and IMRT treatments,
planned with Eclipse. Additionally, all deliveries of all treatments passed the RPC credentialing
criteria. When compared to the average percent of points passing gamma analysis for all institutions
passing head and neck IMRT credentialing, the three treatment techniques evaluated compared
favorably on average.

4.3

Future Work
There are many questions left about the clinical impact of VMAT treatments. The shorter

treatment times, greater spreading of lower doses, and potentially fewer MU involved with VMAT
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may have radiobiological and clinical effects. These should be studied for their effects on cell kill,
tumor control, patient morbidity, late effects, and overall survival.
The complicated combination of the variable gantry rotation speed and dynamic MLC
motion should be further investigated to fully understand their uncertainties. Similarly, the ability of
the TPS to predict the gantry motion should be examined to potentially improve the dose calculation
accuracy.
Lastly, there are several VMAT products available, including linacs capable of delivering
VMAT treatments and TPS for VMAT planning and dose calculation, and some can be used with
multiple vendors. Many combinations of these products should be investigated to encompass the full
range of systems available.
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Chapter 5
5.1

Appendix

Treatment Plan Isodose Distributions

Figure 5-1 Isodose distribution of the Elekta VMAT treatment plan
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Figure 5-2 Isodose distribution of the RapidArc treatment plan
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Figure 5-3 Isodose distribution of the IMRT treatment plan
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Figure 5-4 Posterior-to-anterior dose profile of the Elekta VMAT treatment

5.2
Dose profiles
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Figure 5-5 Inferior-to-superior dose profile of the Elekta VMAT treatment
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Figure 5-6 Posterior-to-anterior dose profile of the RapidArc treatment
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Figure 5-7 Inferior-to-superior dose profile of the RapidArc treatment
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Figure 5-8 Posterior-to-anterior dose profile of the IMRT treatment
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Figure 5-9 Inferior-to-superior dose profile of the IMRT treatment

5.3

Gamma analysis

Figure 5-10 Axial gamma analysis (5%/3mm) of first Elekta VMAT treatment delivery
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Figure 5-11 Sagittal gamma analysis (5%/3mm) of first Elekta VMAT treatment delivery
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Figure 5-12 Axial gamma analysis (5%/3mm) of second Elekta VMAT treatment delivery
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Figure 5-13 Sagittal gamma analysis (5%/3mm) of second Elekta VMAT treatment delivery
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Figure 5-14 Axial gamma analysis (5%/3mm) of second RapidArc treatment delivery
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Figure 5-15 Sagittal gamma analysis (5%/3mm) of second RapidArc treatment delivery
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Figure 5-16 Axial gamma analysis (5%/3mm) of third RapidArc treatment delivery
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Figure 5-17 Sagittal gamma analysis (5%/3mm) of third RapidArc treatment delivery
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Figure 5-18 Axial gamma analysis (5%/3mm) of first IMRT treatment delivery
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Figure 5-19 Sagittal gamma analysis (5%/3mm) of first IMRT treatment delivery
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Figure 5-20 Axial gamma analysis (5%/3mm) of third IMRT treatment delivery
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Figure 5-21 Sagittal gamma analysis (5%/3mm) of third IMRT treatment delivery
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Figure 5-22 Axial gamma analysis (7%/4mm) of first Elekta VMAT treatment delivery
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Figure 5-23 Axial gamma analysis (7%/4mm) of second Elekta VMAT treatment delivery
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Figure 5-24 Axial gamma analysis (7%/4mm) of second RapidArc treatment delivery
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Figure 5-25 Axial gamma analysis (7%/4mm) of third RapidArc treatment delivery
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Figure 5-26 Axial gamma analysis (7%/4mm) of first IMRT treatment delivery
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Figure 5-27 Axial gamma analysis (7%/4mm) of second IMRT treatment delivery
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Table 5-1 The RMS values of leaf deviation (cm) for each moving leaf of both carriages for five deliveries of the first, clockwise arc of the
RapidArc treatment

5.4
MLC Log File Results
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Table 5-2 The RMS values of leaf deviation (cm) for each moving leaf of both carriages for five deliveries of the second, counterclockwise
arc of the RapidArc treatment
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